Compare Moderna, Inc. (MRNA) vs VanEck Semiconductor ETF (SMH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs VanEck Semiconductor ETF — how do they compare? Moderna, Inc. trades at $137.45 (market cap $56.02B), while VanEck Semiconductor ETF trades at $571.14. Which is the better fit depends on your goals.
| MRNA | SMH | |
|---|---|---|
Market Cap | $56.02B | — |
Sector | Health | — |
52-Week High | $174.38 | $668.91 |
52-Week Low | $22.36 | $300.83 |
Enterprise Value | $52.17B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $140.33, down 3.59% on the day, amid mixed signals. The stock has seen volatility, with a 143% surge over the past month driven by positive cancer vaccine trial results (Fox Business, 2026-09-06), but faces headwinds from declining revenue and persistent net losses. Technical analysis shows a bullish overall signal, with support at $138 and resistance at $145, while fundamentals reveal a challenging profit margin of -142.58% for 2026.
The outlook hinges on pipeline successes, particularly in oncology, but high valuation ratios and competitive pressures pose risks. Analyst consensus is cautious, with a $90.08 price target, reflecting skepticism despite recent clinical milestones. Investors should weigh innovation potential against financial sustainability and market sentiment shifts.
SMH (VanEck Semiconductor ETF) trades at $573.73, up 1.19% with strong bullish technical signals from moving averages. The ETF benefits from sustained AI-driven semiconductor demand, highlighted by NVIDIA's $12.9B Hugging Face acquisition and robust earnings. Technical indicators show support at $570 and resistance at $579, with RSI levels in neutral territory suggesting balanced momentum.
Outlook remains positive amid AI infrastructure expansion, though risks include potential US tariffs and market volatility. Institutional interest is growing, with Greenland Capital adding a $678,000 position. The ETF's exposure to leading chipmakers positions it for continued growth, but investors should monitor regulatory developments and competitive dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About VanEck Semiconductor ETF
The fund normally invests at least 80% of its total assets in securities that comprise the target index. The index includes common stocks and depositary receipts of US exchange-listed companies in the semiconductor industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a US exchange. The fund is non-diversified.
Read more on SMH →
